MRI located and transrectal ultrasound-guided transperineal biopsy in diagnosis of prostate cancer / 中国介入影像与治疗学

ABSTRACT

Objective: To explore the value of MRI located and transrectal ultrasound (TRUS)-guided transperineal biopsy of prostate cancer (PCa). Methods: MRI were obtained of 120 patients with suspected PCa, and then systematic biopsy (SB) and MRI-located target biopsy (MRI-TB) guided by TRUS were performed. The detection rate for PCa and positive needle rate of SB, MRI-TB and SB+MRI-TB were respectively calculated according to pathological outcomes. Results: Seventy-eight PCa and 42 benign lesions were proved by pathology. The missed diagnosis rate of SB and MRI-TB for PCa was 23.08% (18/78) and 8.97%(7/78), which were statistically different (P=0.048). The detection rate of PCa for SB, MRI-TB and SB+MRI-TB was 50.00% (60/120), 59.17% (71/120) and 65.00% (78/120), respectively, of SB+MRI-TB was higher than of SB and MRI-TB (both P<0.05). The positive needle rate of PCa for SB, MRI-TB and SB+MRI-TB was 31.17% (374/1 200), 59.58% (286/480) and 35.14% (538/1 531), respectively, of MRI-TB was higher than that of SB and SB+MRI-TB (both P<0.001). Conclusion: MRI-TB can improve the rate of positive biopsy needles, reduce the number of biopsy points and the risk of repeated biopsy and complications. SB+MRI-TB protocol can improve the detection rate of PCa.